{
  "ticker": "BB1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972580",
  "id": "02972580",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250725",
  "time": "0841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m43ms65m9ydt.pdf",
  "summary": "Here\u2019s the concise extraction of material information from the ASX announcement:\n\n### **Quarterly Report (Appendix 4C) Highlights:**  \n- **Clinical Progress:**  \n  - **Autism Trial (U.S.):** Pilot Phase completion on track (163 children tested). Main Phase recruitment to commence Q3 2025; FDA 510(k) pathway progress with IRB approval secured.  \n  - **ADHD Trial (Europe):** Expanded from 1 to 5 sites, targeting ~300 participants by year-end for EU regulatory submission.  \n  - **Recruitment Strategy:** Shifted to broader sources (beyond autism waitlists) to reduce sample size and costs.  \n\n- **Financials:**  \n  - **Cash Balance (30 June 2025):** **A$8.711M** (up from A$3.134M previous quarter).  \n  - **Net Cash Burn (Operating):** **A$1.35M** (QoQ), with **A$0.966M** spent on R&D.  \n  - **Capital Raise:** **A$7.66M** raised (mentioned in CEO commentary, though not detailed in Appendix 4C).  \n\n- **Catalysts:**  \n  - Pilot Phase autism data expected Q3 2025.  \n  - Main Phase autism trial enrolment begins Q3 2025.  \n\n**Omitted:** Operational minutiae, director quotes, non-material expenses.  \n\n*Summary tailored for trading/capital markets focus.*",
  "usage": {
    "prompt_tokens": 6621,
    "completion_tokens": 311,
    "total_tokens": 6932,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T22:59:25.485424"
}